# Treatment Strategy Overview for EGFR+ NSCLC

時間:民國 109 年 12 月 3 日(星期四)18:30~20:10 會議敬備晚餐

地點:台北喜來登飯店 2 樓瑞穗園 (台北市中正區忠孝東路一段 12 號)

時間	題目	演講者	座 長
18:30-18:55	Registration		
18:55-19:00	Opening		<b>陳育民理事長</b> 台灣肺癌學會
19:00-19:30 視訊會議	EGFR talks	Dr. Marina Garassino (Italy) Dr. Ernest Nadal (Spain)	

視訊會議【敬請事先報名,謝謝配合。】

報名連結 <a href="https://e.lilly/326a8yf">https://e.lilly/326a8yf</a> 或 掃描 QR code 報名 → 會議報名步驟,請見下頁 視訊會議註冊說明



19:30-20:00 實體會議	Update current treatment algorithm for EGFR mutant NSCLC	施金元 主任 台大醫院胸腔科	<b>陳育民理事長</b> 台灣肺癌學會
20:00-20:10	Closing Remarks		<b>陳育民理事長</b> 台灣肺癌學會

主辦單位:台灣肺癌學會

協辦單位:台灣禮來股份有限公司

教育積分:台灣肺癌學會、台灣胸腔暨重症加護醫學會、


台灣臨床腫瘤醫學會、中華民國癌症醫學會、

社團法人臺灣臨床藥學會 藥師學分

中華民國護理師護士公會全國聯合會 護理師學分

中華民國護理師護士公會全國聯合會 專科護理師學分

## 視訊會議註冊說明



### Summary

During this interactive webinar, Dr. Ernest Nadal and Dr. Marina Garassino will lead a discussion associated to the newest indication of Cyramza in combination with Erlotinib for EGFR + NSCLC patients and its impact in clinical practice followed by a live Q&A session.

Country Prescriber Information: Austria, Brazil, Germany Greece, Hong Kong Korea, Netherlands, Taiwan

This webinar includes comprehensive information on Lilly products and/or devices, with an approved indication in a set group of countries. It is intended for a specific group of Healthcare Professionals (HCP) working on a country within the list, and invitations have been sent by Lilly personnel only to these HCPs. If you have not received the invitation from a Lilly employee, please ask your Lilly contact if the content is approved in your country.

#### Speakers



#### Dr. Ernest Nadal

Head of the Section of Thoracic Tumors, Department of Medical Oncology

Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain

Head of the Section of Thoracic Tumors, Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain. He is an assistant Professor at the University of Barcelona, Department of Clinical Sciences, Campus Bellvitge, L'Hospitalet, Barcelona, Spain. He is the principal investigator of the Clinical Research in Solid Tumors (CReST) group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain. He has published more than 50 papers including papers in high impact journals in the field of oncology and cancer biology



#### Dr. Marina Garassino

Chief of the Thoracic Oncology Unit Istituto Nazionale dei Tumori, Milano

Chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori, Milano. As the chief she is responsible for leading the strategy for clinical and translational research in advanced and locally advanced NSCLC, mesothelioma and thymic malignancies. She has contributed to over 160 peer-reviewed publications, including publications as first or last author in the Lancet Oncology, JCO, Annals of Oncology and New England Journal of Medicine. She had several presentations at international congresses including ASCO, ESMO, ECCO and WCLC.

